{"id":16981,"date":"2021-10-31T17:06:40","date_gmt":"2021-10-31T04:06:40","guid":{"rendered":"https:\/\/clladvocates.nz\/?p=16981"},"modified":"2021-10-31T17:06:40","modified_gmt":"2021-10-31T04:06:40","slug":"sars-cov-2-igg-serology-testing-2","status":"publish","type":"post","link":"https:\/\/clladvocates.nz\/?p=16981","title":{"rendered":"SARS-CoV-2 IgG Serology Testing"},"content":{"rendered":"

[vc_row row_height_percent=”0″ override_padding=”yes” h_padding=”2″ top_padding=”3″ bottom_padding=”3″ overlay_alpha=”50″ gutter_size=”3″ column_width_percent=”100″ shift_y=”0″ z_index=”0″][vc_column column_width_percent=”100″ gutter_size=”3″ overlay_alpha=”50″ shift_x=”0″ shift_y=”0″ shift_y_down=”0″ z_index=”0″ medium_width=”0″ mobile_width=”0″ width=”1\/1″ uncode_shortcode_id=”643170″][vc_custom_heading heading_semantic=”h1″ text_size=”h1″ uncode_shortcode_id=”177358″]<\/p>\n

SARS-CoV-2 IgG Serology Testing<\/b><\/h2>\n

[\/vc_custom_heading][vc_column_text uncode_shortcode_id=”166781″]<\/p>\n

\n
\n<\/div>\n

Please note effective\u00a014th June<\/b>, SARS-CoV-2 IgG serology testing will be available at Pathlab.<\/u><\/u><\/p>\n

This assay can potentially be used to assess vaccine response and to detect previous infection.<\/u><\/u><\/p>\n

This is a quantitative IgG assay performed on the Abbott Alinity platform. However, as it is still not clear exactly what level of antibodies confers reliable protection against COVID-19 post-vaccination, we will report positive and negative IgG results in a qualitative manner in the first instance, along with qualifying comments as below:<\/u><\/u><\/p>\n

Positive<\/b>\u00a0\u201cIgG antibodies to SARS-CoV-2 spike protein DETECTED. This result indicates prior exposure to SARS-CoV-2 or vaccination. Antibody levels peak approximately 2 weeks after infection or second dose of vaccine, with variable duration of measurable antibody. The presence of antibodies is likely to be associated with current protection from symptomatic COVID-19 infection, but a true serological correlate of protection has not yet been established.\u201d<\/u><\/u><\/p>\n

Negative<\/b>\u00a0\u201cIgG antibodies to SARS-CoV-2 NOT detected. A proportion of mild cases of COVID-19 do not produce durable antibodies. The presence of antibodies is likely to be associated with current protection from symptomatic COVID-19 infection, but a true serological correlate of protection has not yet been established. Absence of measurable antibodies after vaccination does not necessarily imply lack of immunity.\u201d Please ensure relevant clinical history and COVID-19 vaccination status (including date of vaccination) is on the request form.<\/u><\/u><\/p>\n

Please note – this assay is not currently funded so the patient will be charged.<\/u><\/u><\/p>\n

This test must be requested by a clinician and is not currently available by self-request.<\/b><\/p>\n

[\/vc_column_text][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

This assay can potentially be used to assess vaccine response and to detect previous infection.<\/p>\n","protected":false},"author":1,"featured_media":16974,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[12,17,22],"tags":[],"class_list":["post-16981","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news-media","category-featured","category-covid19"],"jetpack_featured_media_url":"https:\/\/clladvocates.nz\/wp-content\/uploads\/2021\/10\/thumbnail_image004.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts\/16981","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=16981"}],"version-history":[{"count":1,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts\/16981\/revisions"}],"predecessor-version":[{"id":16987,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts\/16981\/revisions\/16987"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/media\/16974"}],"wp:attachment":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=16981"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=16981"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=16981"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}